Method: Shotgun metagenomic sequencing (CLIA 21D2062464); not cleared or approved by the FDA. Results reflect relative microbial abundance for wellness education purposes. Not intended to diagnose or treat disease and not a substitute for clinical consultation. Microbial associations are based on emerging scientific research and may change over time.
A derived biomarker is a value that is calculated from other directly measured biomarkers rather than being measured directly in the lab.
Key benefits of Acinetobacter baumannii testing
- Multidrug-resistant opportunistic pathogen monitoring
- nosocomial exposure tracking
What is Acinetobacter baumannii?
Acinetobacter baumannii is a gram-negative bacterium known primarily as a healthcare-associated (nosocomial) pathogen with significant antibiotic resistance. Its detection in the gut microbiome by shotgun sequencing may indicate recent healthcare exposure or environmental acquisition.
Why is Acinetobacter baumannii important?
A. baumannii is of particular concern given its multidrug resistance potential. While primarily an opportunistic pathogen in hospital settings, detection in the gut microbiome may reflect recent healthcare contact or exposure to healthcare environments and is worth monitoring.
What insights will I get?
Detection of A. baumannii in your sample may reflect recent healthcare exposure. Discuss this finding with your care team, particularly in the context of your antibiotic resistance marker levels.





.avif)
.avif)

